02142 and 6XY Related Headlines
Go Back- Harbour BioMed Announces Positive Profit Alert for 2025 Annual Results
- Harbour BioMed Acquires Common Stock in Spruce Biosciences, Deepening Strategic Collaboration
- Harbour BioMed Enters into Long-Term Strategic Collaboration with Lannacheng to Advance Next-Generation Radionuclide Drug Conjugates
- Harbour BioMed partners with Bristol Myers Squibb on antibody development
- Harbour BioMed Enters into Global Strategic Collaboration and License Agreement with Bristol Myers Squibb to Discover and Develop Next-Generation Multi-Specific Antibodies
- Harbour BioMed Advances Global Strategic Collaboration with AstraZeneca to Discover and Develop Next-Generation Biotherapeutics in Oncology
- Harbour BioMed and Evinova China Announce Strategic AI Collaboration to Accelerate AI-Enabled Drug Development
- Harbour BioMed Launches First Fully Human Generative AI HCAb Model to Accelerate Next-Generation Biologics Discovery
- Harbour BioMed Announces Positive Phase II Results for HBM4003 and Tislelizumab Combination in MSS mCRC
- Harbour BioMed Reports 2025 Interim Results
- Harbour BioMed names Yajie Li as chief medical officer
- Harbour BioMed names Yajie Li as chief medical officer
- Harbour BioMed Appoints Yajie Li as Chief Medical Officer
- Harbour BioMed to Present Phase II Data of HBM4003 and Tislelizumab Combination in MSS Metastatic Colorectal Cancer at ESMO 2025
- Harbour BioMed Announces Positive Profit Alert for 2025 Interim Results
- Harbour BioMed partner starts phase 2 asthma drug trial
- HBM9378/WIN378, a Long-Acting, Fully Human Anti-TSLP Antibody, Enters Global Phase 2 POLARIS Trial for Asthma
- Harbour BioMed Enters Global Strategic Collaboration with Otsuka to Advance BCMAxCD3 Bispecific T-Cell Engagers
- China National Intellectual Property Administration Affirms Validity of Harbour BioMed's Patent; Infringement Lawsuit Moves Forward
02142 and 6XY Related Press Releases
Go Back- Harbour BioMed Announces Positive Profit Alert for 2025 Annual Results
- Harbour BioMed Acquires Common Stock in Spruce Biosciences, Deepening Strategic Collaboration
- Harbour BioMed Enters into Long-Term Strategic Collaboration with Lannacheng to Advance Next-Generation Radionuclide Drug Conjugates
- Harbour BioMed Enters into Global Strategic Collaboration and License Agreement with Bristol Myers Squibb to Discover and Develop Next-Generation Multi-Specific Antibodies
- Harbour BioMed Advances Global Strategic Collaboration with AstraZeneca to Discover and Develop Next-Generation Biotherapeutics in Oncology
- Harbour BioMed and Evinova China Announce Strategic AI Collaboration to Accelerate AI-Enabled Drug Development
- Harbour BioMed Launches First Fully Human Generative AI HCAb Model to Accelerate Next-Generation Biologics Discovery
- Harbour BioMed Announces Positive Phase II Results for HBM4003 and Tislelizumab Combination in MSS mCRC
- Harbour BioMed Reports 2025 Interim Results
- Harbour BioMed Appoints Yajie Li as Chief Medical Officer
- Harbour BioMed to Present Phase II Data of HBM4003 and Tislelizumab Combination in MSS Metastatic Colorectal Cancer at ESMO 2025
- Harbour BioMed Announces Positive Profit Alert for 2025 Interim Results
- HBM9378/WIN378, a Long-Acting, Fully Human Anti-TSLP Antibody, Enters Global Phase 2 POLARIS Trial for Asthma
- Harbour BioMed Enters Global Strategic Collaboration with Otsuka to Advance BCMAxCD3 Bispecific T-Cell Engagers
- China National Intellectual Property Administration Affirms Validity of Harbour BioMed's Patent; Infringement Lawsuit Moves Forward
